Radiopharm Theranostics has increased its stake in the Radiopharm Ventures joint venture with the University of Texas MD Anderson Cancer Center from 75 % to 87.5 %, giving the company majority control of the partnership’s portfolio, which includes the B7H3‑targeted radioligand Betabart (RV01) and several other preclinical candidates.
The joint venture was formed in September 2022 with Radiopharm holding a 51 % share and MD Anderson 49 %. Radiopharm later raised its stake to 75 % in August 2024, and the latest increase to 87.5 % further consolidates its position and allows it to capture a larger portion of any future commercial revenue and milestone payments from the venture’s assets.
Betabart received FDA IND clearance in July 2025 and is slated to begin first‑in‑human dosing in the first quarter of 2026. The program’s progress, combined with the other preclinical candidates that are expected to enter selection in 2026, underpins Radiopharm’s confidence in the joint venture’s commercial potential.
CEO Riccardo Canevari said the company is "very encouraged by the progress to date within Radiopharm Ventures" and that the timing of the ownership increase aligns with the upcoming first‑in‑human results for Betabart. He added that the move reflects confidence in the program’s value and its potential to benefit patients battling a variety of solid tumors.
The ownership change strengthens Radiopharm’s partnership with MD Anderson, a leading cancer research institution, and positions the company to play a more decisive role in the development and commercialization of the joint venture’s pipeline. By holding a majority stake, Radiopharm can influence strategic decisions, accelerate development timelines, and secure a larger share of future revenue streams as the portfolio moves toward regulatory approval and market launch.
The move also signals Radiopharm’s commitment to its radiopharmaceutical strategy, which focuses on novel oncology targets such as B7H3 rather than more crowded “me‑too” targets. The company’s broader pipeline includes imaging agents for brain metastases, prostate cancer, and PD‑L1‑positive advanced cancers, underscoring its diversified approach to oncology therapeutics.
While the announcement does not provide specific financial metrics for Radiopharm, the increased ownership stake is expected to enhance the company’s cash‑flow profile once the joint venture’s assets reach commercialization, thereby supporting future growth initiatives and potential capital deployment.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.